Adlai Nortye combines explosive revenue growth with severe cash burn, an unreliable analyst price target, and a business-quality score below the investment floor, leaving the growth narrative overshadowed by financial and data-quality concerns.
Thesis pillars
- Explosive Revenue Growth→Stable
- Severe Cash Burn→Stable
- Unreliable Analyst Target Data↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 6, 2026
Adlai Nortye Group Ltd. (ANL) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 10.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an... Read more
Sell if holding. Engine safety override at $10.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 10.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Adlai Nortye Group Ltd.
Latest news
- NEWS Adlai Nortye Announces Oral Presentation for AN4035 Program Update at ENA Symposium — fiscal.ai Oct 27, 2026 positive
- NEWS Adlai Nortye Group Reveals Oral Presentation For AN4035 Program Update At the Upcoming 38th EORTC-NCI-AACR Symposium — benzinga Oct 27, 2026 neutral
- NEWS Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday — benzinga Oct 15, 2026 neutral
- NEWS Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBIT — benzinga Oct 15, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $20 Price Target — benzinga Sep 8, 2026 neutral
Generated 2026-10-29T11:14:31Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Unprofitable operations — net margin -124.8%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 10.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $9.74. Score 4.7/10, moderate confidence.
Analyst target: $25.66 (+151.6% upside). Prior stop was $9.74. Stop-loss: $9.74.
Quality below floor (3.4 < 4.0).
Adlai Nortye Group Ltd. trades at a P/E of N/A (forward -34.7). TrendMatrix value score: 5.4/10. Verdict: Sell.
11 analysts cover ANL with a consensus score of 4.3/5. Average price target: $30.
What does Adlai Nortye Group Ltd. do?Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer...
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.